A New Treatment for Severe Pancreatitis
Official title: One Health Advancement of RABI-767 for the Management of Acute Pancreatitis
Funded at Lamassu Pharma INC. · NIH-11124672 · Data updated 2026-11-12
This work explores a new medicine, RABI-767, to help manage severe acute pancreatitis in both people and animals.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lamassu Pharma INC. NIH-funded |
| Lab location | 1 site (Durham, UNITED STATES) |
| Project start | July 7, 2020 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $866,665 |
| NIH project number | 5R44DK125219-04 |
| Project ID | NIH-11124672 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is foundational for patients who experience acute pancreatitis, especially those at risk of developing severe forms of the condition.
✕Less likely to help
Patients with other conditions not related to acute pancreatitis would not directly benefit from this specific treatment.
What this research studies
Acute pancreatitis can become very serious, leading to organ failure, and currently, there isn't an effective treatment. This project focuses on a new medicine called RABI-767, which aims to stop the harmful processes that turn mild pancreatitis into a severe condition. Researchers believe that by blocking certain enzymes, RABI-767 can prevent organ damage and widespread inflammation. The initial phase involves a trial in dogs with spontaneous acute pancreatitis to understand how the medicine works and find the best way to give it. The information gathered from these studies will then help design future human clinical trials.
Why it matters
Potential benefit: If successful, this new medicine could offer the first effective treatment for severe acute pancreatitis, potentially preventing organ failure and improving patient outcomes.
How similar studies have gone: This approach builds on existing clinical and preclinical data, and prior work has shown that inhibiting certain enzymes can reduce organ failure in animal models of severe acute pancreatitis.
Where this research is happening
-
Lamassu Pharma INC.
Durham, United States Active
Researchers
- Principal investigator: Hanna, Gabi — Lamassu Pharma INC.
- Study coordinator: Hanna, Gabi
Related research
Other NIH-funded projects on the same topics.
-
Diabetes after acute pancreatitis: understanding and tracking progression
A patient-focused look at how diabetes can develop after an episode of acute pancreatitis, using data from a large, ongoing study and AI insights.
-
Continuation of Type 1 Diabetes in Acute Pancreatitis: UF Health and AdventHealth
A patient-facing overview of a long-term study tracking people with acute pancreatitis to understand how some develop type 1 diabetes later and what factors influence that process.
-
Data Coordinating Center for Type 1 Diabetes in Acute Pancreatitis Consortium
A national effort to learn how pancreatitis-related Type 1 diabetes develops, by tracking patients and coordinating data to improve future care.
-
Diabetes after acute pancreatitis: a patient-focused network study
A program at Indiana University is studying how diabetes can develop after an acute pancreatitis episode, with new findings that could help doctors tailor care for adults who had pancreatitis.
-
Type 1 Diabetes in Acute Pancreatitis in Diabetes Patients at Stanford
A Stanford-led project helps people with brittle type 1 diabetes who also experience pancreatitis by following them in a long-term study to understand how acute pancreatitis affects diabetes.
-
Epidemiology and causes of diabetes after acute pancreatitis
A long-term study following people who have had acute pancreatitis to understand how often diabetes develops, why it happens, and how it progresses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.